Open Access
ARTICLE
Berberine inhibits the proliferation of pancreatic cancer cells by targeting pancreatic cancer stem cells through regulating EMT signaling pathway
1 State Key Laboratory of Fine Chemicals, Department of Pharmaceutical Sciences, School of Chemical Engineering, Dalian University of Technology, Dalian,
116023, China
2 Ningbo Institute of Dalian University of Technology, Ningbo, 315000, China
3 Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450000, China
4 Henan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou University, Zhengzhou, 450000, China
* Corresponding Authors: Yongjie Yang, ; Gary Guishan Xiao,
# These authors have contributed equally to this work and share first authorship
BIOCELL 2022, 46(10), 2257-2265. https://doi.org/10.32604/biocell.2022.020325
Received 17 November 2021; Accepted 07 February 2022; Issue published 13 June 2022
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is universally acknowledged as the cancer with the highest mortality rate. Berberine has high medicinal value and has been used as an anti-cancer agent. Hence the purpose of this study was to investigate the anti-cancer effect of berberine in PDAC. Berberine was shown to have a selective anti-cancer effect on PDAC by MTT assay in vitro. Pancreatic cancer stem cells (PCSCs), regulated by epithelial–mesenchymal transition (EMT), could promote the proliferation of PDAC cells. However, berberine suppressed the proliferation and stemness of PCSCs through immunofluorescence staining, stem cell sphere assays and so forth in vitro. In vivo, berberine reduced tumor size and decreased the expression levels of Ki67, a marker of cellular proliferation, in orthotopic pancreatic tumors. In addition, berberine inhibited the EMT signaling pathway by RT-PCR and Western blotting methods both in vitro and in vivo. Our study indicates that berberine inhibits the proliferation of PDAC cells both in vivo and in vitro. The mechanism of the anti-cancer effect of berberine likely involves the inhibition of EMT. Therefore, berberine may be a novel antineoplastic drug with clinical efficacy in PDAC.Keywords
Cite This Article
This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.